Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 15/20 | 0.67 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.67 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | EPN1 | Q9Y6I3 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15484324 | 0.82 | ALOX15 (0.48) | HCAR2HCAR3DAOALOX15 | |
| SCHEMBL1739326 | 0.80 | HCAR2 (1.00) | HCAR2HCAR3DAOCYTH3BTK | |
| Hydrochloric Acid SCHEMBL31467457 | 0.78 | HCAR2 (0.96) | HCAR2HCAR3DAOCYTH3BTK | |
| SCHEMBL5599627 | 0.78 | HCAR2 (0.76) | HCAR2HCAR3DAOCYTH3BTK | |
| SCHEMBL25427901 | 0.78 | MAPK1 (0.59) | HCAR2HCAR3ALOX15MEN1KMT2A | |
| SCHEMBL5600049 | 0.77 | HCAR2 (0.57) | HCAR2HCAR3DAO | |
| SCHEMBL5599868 | 0.74 | HCAR2 (0.69) | HCAR2HCAR3DAOCYTH3BTK | |
| SCHEMBL5599290 | 0.74 | HCAR2 (0.69) | HCAR2HCAR3DAOCYTH3BTK | |
| SCHEMBL5599520 | 0.74 | HCAR2 (0.69) | HCAR2HCAR3DAOCYTH3BTK | |
| SCHEMBL4178432 | 0.74 | KMT2A (0.49) | HCAR2HCAR3ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746964-A1 | NEW PYRAZOLOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026046976-A1 | PYRAZOLOPYRIDINE PHOSPHATE ESTERS FOR MODULATING SALT-INDUCIBLE KINASE (SIK) | F. HOFFMANN-LA ROCHE AG (CH) | 2026-03-05 | — | — | WO | disclosed |
| WO-2025096658-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096662-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025017078-A1 | NEW PYRAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-4291176-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117136052-A | CDK inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-11-28 | — | — | CN | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20100120839-A1 | PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB | 2010-05-13 | — | — | US | disclosed |
| CN-101687861-A | Pyrazoles useful in the treatment of inflammation | BIOLIPOX AB | 2010-03-31 | — | — | CN | disclosed |
| EP-2146983-A1 | PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20090143440-A1 | Pyrazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143455-A1 | Pyrazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-06-04 | — | — | US | disclosed |
| CN-101331118-A | Pyrazoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2008-12-24 | — | — | CN | disclosed |
| WO-2008129280-A1 | PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| EP-1943241-A1 | PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1937645-A1 | PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007051981-A1 | PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007045868-A1 | PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120839-A1 | PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | ALOX15, ALOX12, ALOX15B | HCAR2 309/4885HCAR3 646/4885DAO 661/4885 |
| US-20090143440-A1 | Pyrazoles Useful in the Treatment of Inflammation | ALOX15, ALOX12, ALOX15B | HCAR2 488/4885HCAR3 986/4885DAO 783/4885 |
| US-20090143455-A1 | Pyrazoles Useful in the Treatment of Inflammation | ALOX15, ALOX12, ALOX15B | HCAR2 580/4885HCAR3 1074/4885DAO 797/4885 |
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | CDK3, CDK8, CDK6 | HCAR2 4227/4885HCAR3 4049/4885DAO 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.